baber/WOPTO huggingface dataset:
Patent NZ-511741-A (NZ)
Title: Bearing with mounting that facilitates cushioning and electric motor utilising same.
Inventor: MCCALLUM STEVEN MURRAY
IPC: F16C19/54
Filed: 2001-05-15
Abstract: A bearing assembly which includes at least two coaxial side-by-side rolling type bearings, each bearing being provided with at least one mounting seal, each seal comprising a ring of resilient material which is arranged to contact the external circumference of the corresponding bearing such that in use each bearing is mounted, independently of the other bearings, upon the corresponding seal or seals.
Patent NZ-516381-A (NZ)
Title: Lung tumor proteins in the therapy and diagnosis of lung cancer
Inventor: RETTER MARC W
IPC: C12Q1/68
Filed: 2000-06-30
Abstract: An isolated polypeptide comprising at least an immunogenic portion of a lung tumor protein, a polynucleotide sequence encoding the polypeptide, antibodies raised against the lung tumor protein, pharmaceutical compositions and their uses for inhibiting the development of cancer in a patient
Patent NZ-519191-A (NZ)
Title: Antibodies that bind to domain 1 of ErbB2 useful for inducing cell death via apoptosis, and nucleic acids encoding such antibodies
Inventor: FENDLY BRIAN M
IPC: A61K31/407
Filed: 1997-10-09
Abstract: Anti-ErbB2 antibodies are described that bind to an epitope in Domain 1 of ErbB2 and induce cell death via apoptosis. Various uses for these antibodies are also described. The figure shows the epitope specificity of anti-ErbB2 antibodies. MAbs were used to block the binding of 7C2 to BT474 cells. BT474 cells (0.5 x 106) pre-treated or not with 50 micrograms anti-ErbB2 antibodies (15 minutes on ice) were washed twice, resuspended in 0.lml 1% FBS/PBS and incubated with 5 micrograms of fluoresceinisothiocyanate (FITC) conjugated 7C2 antibody (15 minutes on ice). Following incubation, the cell suspensions were washed twice with 1% FBS/PBS to remove unbound fluorochrome, fixed with 1% paraformaldehyde/PBS and analysed by flow cytometry. (62) Divided out of 508525
Patent NZ-520186-A (NZ)
Title: Stain removing chewing gum and confectionery compositions, and methods of making and using the same
Inventor: LUO SHIUH JOHN
IPC: A23L29/10
Filed: 2001-03-01
Abstract: A stain removing chewing gum composition comprising: a) a core, and b) an optional coating having at least one layer. The coating comprising a stain removing effective amount of at least one stain removing agent selected from the group - sodium stearate, sodium palmitate, organic acid esters of mono- and/or diglycerides. The stain removing agent is not directly mixed with the gum base when producing the chewing gum composition so as to enable the stain removing agent to be effectively released from the chewing gum composition.
Patent NZ-520890-A (NZ)
Title: Sheeting with composite image that floats
Inventor: FLORCZAK JEFFREY M
IPC: G02B27/22
Filed: 2000-06-20
Abstract: Microlens sheetings with composite images are disclosed, in which the composite image floats above or below the sheeting, or both. The composite image may be two-dimensional or three-dimensional. Methods for providing such an imaged sheeting, including by the application of radiation to a radiation sensitive material layer adjacent the microlenses, are also disclosed.
Patent NZ-522616-A (NZ)
Title: Highly fluid concrete composition containing a silica sol and a polycarboxylate superplastciser and its preparation method
Inventor: GREENWOOD PETER
IPC: C04B28/02
Filed: 2001-04-06
Abstract: Concrete composition comprising a hydraulic binder, aggregates, water, silica sol and a superplasticiser, wherein that the superplasticiser is a polycarboxylate, and a method for preparation thereof and use of the prepared concrete composition as high fluidity concrete is disclosed.
Patent NZ-533256-A (NZ)
Title: Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
Inventor: MENG XIANG-JIN
IPC: A61K39/00
Filed: 2002-12-11
Abstract: Disclosed is an infectious chimeric nucleic acid molecule of porcine circovirus (PCV1-2) characterised by having a nucleic acid molecule encoding an infectious, non-pathogenic PCV1 which contains an immunogenic open reading frame (ORF) gene of a pathogenic PCV2 in place of an ORF gene of the PCV1 nucleic acid molecule. Also disclosed is the porcine circovirus encoded by the above nucleic acid and vaccines containing the virus.
Patent NZ-535195-A (NZ)
Title: Compositions containing labile bioactive materials and mammalian colostrum, methods of preparation and treatment
Inventor: LICHTI GOTTFRIED
IPC: A61K35/74
Filed: 2003-03-21
Abstract: An in vitro method of improving the viability of a labile bioactive substance on administration to a hostile environment, wherein said method comprises the step of forming a mixture of the bioactive substance and mammalian colostrum.
Patent NZ-535306-A (NZ)
Title: Printable envelope with l-shaped addition
Inventor: MACEWEN TAMARA L
IPC: B65D27/14
Filed: 2003-01-07
Abstract: A printable envelope assembly suitable for loading into a standard size paper tray of a printer, comprising: an envelope (20); and a generally L-shaped paper carrier member (30) releasably adhered to the envelope (20); wherein the envelope and the L-shaped member together define a generally flat paper assembly having a length and a width approximately equal to a standard paper size.
Patent NZ-536378-A (NZ)
Title: Embossing apparatus
Inventor: VAUGHN JEFFREY MOSS
IPC: B31F1/07
Filed: 2003-06-06
Abstract: An apparatus for embossing a web material, comprising: (a) a first embossing roll having a first embossing pattern engraved on at least a portion of the peripheral surface of the first roll, the first embossing pattern comprising protrusions and recessions; and (b) a second embossing roll having a second embossing pattern engraved on at least a portion of the peripheral surface of the second embossing roll, the second embossing pattern comprising protrusions and recessions. The protrusions of the first embossing pattern of the first embossing roll become inter-engaged at a radial depth of engagement with the corresponding recessions of the second embossing pattern of the second embossing roll such that at least 99.7% of the inter-engaged protrusions and recessions are separated from each other by a sidewall clearance ranging from about 0.002'' (about 0.050 mm) to about 0.050'' (about 1.27 mm).
Patent NZ-538808-A (NZ)
Title: Vaccines against west nile virus
Inventor: UYTDEHAAG ALPHONSUS GERARDUS C
IPC: C07K14/18
Filed: 2003-11-07
Abstract: Vaccines containing (whole-inactivated) West Nile Viruses and/or West Nile viral proteins derived there from, produced on human cells, wherein the human cells comprise a sequence encoding at least one early region-1 (El) gene product of an adenovirus. The cells are preferably cultured in suspension to very high densities and under serum-free conditions. Also disclosed is the use of such cells results in high titers of West Nile Virus produced.
Patent NZ-539687-A (NZ)
Title: Multi-layered forming fabric with a top layer of twinned wefts and an extra middle layer of wefts
Inventor: ROUGVIE DAVID S
IPC: D21F1/00
Filed: 2003-10-14
Abstract: A papermaker's fabric, usable in the forming section of a paper machine, has three layers of cross-machine-direction (CD) wefts. The forming layer wefts are grouped into pairs. This twinning of the top-layer wefts results in non-equal spacing in the forming (top) layer. This spacing imparts a desired non-uniformity in the web-supporting surface, thereby reducing diagonal fabric pattern. The forming layer wefts are vertically offset from the middle and wear side layer wefts, which are vertically stacked. This unstacked alignment reduces the caliper of the fabric and lowers the void wefts provide extra stability in the CD.
Patent NZ-541281-A (NZ)
Title: Sintered multifilament Bi2223 oxide superconductor wire with silver sheath
Inventor: KOBAYASHI SHINICHI
IPC: H01L39/24
Filed: 2004-08-04
Abstract: An oxide superconducting wire includes a plurality of longitudinally extending filaments of oxide superconductor, each filament including the Bi2223 phase and having a sintered density of at least 95%, the filaments being covered by a sheath of silver or silver alloy.
Patent NZ-546480-A (NZ)
Title: Pressurised water releasing nozzle for generating microbubbles in a flotation plant
Inventor: VION PATRICK
IPC: B01F23/00
Filed: 2004-10-05
Abstract: An expansion nozzle for pressurized water for generating micro-bubbles in a floatation installation includes a first diaphragm expansion stage 1, an intermediate transit chamber 2, a second diaphragm expansion stage 3 and an outlet tube 4. The diameter d1 of the hydraulic orifice of the first expansion stage is about 1.5 times the diameter d2 of the orifice of the second expansion stage. The pressure drop across the first diaphragm is about 15%, across the transit chamber about 15%, and most of the pressure loss of 70% occurs across the second diaphragm expansion stage where the pressure of the water changes from saturation pressure in the transit chamber to the outlet pressure of the nozzle. The outlet tube 4 is an abrupt expansion and cavitation confinement pipe with a minimum length L corresponding to the distance separating the end of the tube at the same side of the second expansion stage from the point of sticking of the jets to the walls of the tube, with a jet divergence angle, before sticking, of between 3 and 12 degrees.
Patent NZ-548381-A (NZ)
Title: Laser calibration device
Inventor: SERGYEYENKO OLEKSIY P
Filed: 2005-02-08
Abstract: A laser calibration device is disclosed which comprises: (a) a housing (22); (b) a pendulum (26) pivotally coupled to the housing (22) and suspending downwards therefrom; (c) a laser deck (28) mounted to the pendulum (26), where the laser deck (28) includes a plurality of laser mounting structures; and (d) a plurality of lasers (30) each mounted to a respective one of the plurality of laser mounting structures, where each of the plurality of lasers (30) is pivotally and rotatably mounted to the laser deck (28).
Patent NZ-554731-A (NZ)
Title: Novel Intermediates Useful For The Preparation Of Aripiprazole And Methods For The Preparation Of The Novel Intermediates And Aripiprazole
Inventor: CHINNAPILLAI RAJENDIRAN
IPC: C07D215/22
Filed: 2004-10-08
Abstract: The disclosure relates to a process for the preparation of aripiprazole (1) which comprises (i) Reacting 6-hydroxy-1-indanone (11) with 1,4-dihalobutane (12) in the presence of a base and a solvent at a temperature in the range of 90 to 110 deg C to form the intermediate 6-(4-halo butoxy)-indan-1-one (3), (ii) reacting the intermediate (3) of step (i) with 1-(2,3-clichlorophenyl)-piperazine (9) to get another intermediate 6-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl] butoxy]-indan-1-one (2) and (iii) Reacting the resulting compound with sodium azide. The disclosure also relates to the intermediates of the formulae (2) & (3) and processes for their preparation.
Patent NZ-556464-A (NZ)
Title: Elastic fixing element in form of head connected to loop by neck, with stubs on head and loop for enhancing installation
Inventor: BOSMANS FRANK
IPC: A01G17/08
Filed: 2006-01-04
Abstract: The disclosure relates to an elastic fixing element and a coherent arrangement of such elements. Said elastic fixing elements are especially used to hold together first and second especially rectilinear elements, such as a vine stem or a branch and a supporting metallic wire. The inventive elastic element comprises a closed loop, a head, and a neck which connects the head to the closed loop. The head is extended by an upper protrusion. The closed loop is extended by a lower protrusion, enabling the elastic element to be manually positioned around the elements to be fixed.
Patent NZ-561400-A (NZ)
Title: Controlled release formulations of octreotide
Inventor: KUZMA PETR
IPC: A61K38/08
Filed: 2006-03-10
Abstract: An implant comprising a hydrogel, octreotide, and a hydrophilic excipient is disclosed, wherein: said octreotide is contained within said hydrogel which comprises a copolymer obtained from the copolymerization of a mixture comprising at least two hydrophilic, ethylenically unsaturated monomers; said implant contains from about 20 to about 150 milligrams of octreotide, in free form or salt form; said implant provides an in vivo average steady state concentration (Css) of about 0.1 ng/ml to about 9 ng/ml of octreotide in a patient over a period of at least about two months; and said hydrophilic excipient is selected from the group consisting of dextran, an hydroxyalkyl cellulose, albumin, and tocopherol propylene glycol succinate. These implants are suitable for subcutaneous administration for the treatment of acromegaly or symptoms associated with acromegaly in a patient in need thereof.
Patent NZ-574529-A (NZ)
Title: Flexibility assesment apparatus comprising a spine with a measuring ruler, footplates and heel rests
Inventor: STRANG ALAN WAYNE
IPC: A61B5/11
Filed: 2007-06-29
Abstract: A sit and reach flexibility assessment apparatus is disclosed. The apparatus comprises a spine (7) with a measuring rule (12). There are footplates (18 and 19) mounted on each side of the spine (7). The footplates (18 and 19) are rotatable from a stowed position to an open position at right angles to the plane of the spine (7). Heel rests (25 and 26) are connected at the base of the footplates (18 and 19) and rotatable from a stowed position to an open position at right angles to the footplates (18 and 19) and the spine (7). A user can sit with heels in heel rests (25 and 26) and lean forward to move indicator (13) to provide indication of flexibility.
Patent NZ-578079-A (NZ)
Title: Method for determining the stability of organic methyleneamines in the presence of semicarbazide-sensitive amine oxidase
Inventor: ADEDOYIN ADEDAYO
IPC: C12N15/00
Filed: 2008-01-08
Abstract: 578079 Provided is method of determining the metabolic stability of a test agent due to semicarbazide sensitive amine oxidase (SSAO) catalyzed metabolism, wherein the test agent is a drug candidate and the metabolic stability of the test agent due to SSAO catalyzed metabolism is unknown, the method comprising: a) culturing recombinant cells expressing full-length SSAO; b) adding a test agent to the cells; c) incubating the test agent with the cells for a predetermined period of time; d) measuring the amount of the test agent remaining in the presence of the recombinant cells expressing SSAO at the predetermined period of time; and e) comparing the amount of the test agent measured in step (d) to the amount of test agent in a control to determine the metabolic stability of the test agent in the presence of the recombinant cells expressing SSAO. The test agents may be radiolabelled.
Patent NZ-578351-A (NZ)
Title: Compositions and methods for the treatment of tumor of hematopoietic origin using CD22 TAHO polypeptides
Inventor: CROWLEY CRAIG
IPC: C07K16/30
Filed: 2004-11-16
Abstract: Disclosed are CD22 Tumour Antigen of Haematopoietic Origin (THAO) proteins having at least 80% amino acid sequence identity to: (a) A polypeptide having the amino acid sequence shown in SEQ ID NO: 51 in figures 51A and B with or with its associated signal peptide; (b) A polypeptide encoded by the nucleotide sequence shown in SEQ ID NO: 50 in Figures 50A and B; or (c) A polypeptide encoded by the full-length coding region shown in SEQ ID NO: 50 in Figures 50A and B. Also disclosed are antibodies that bind the THAO that are conjugated via a peptidase-sensitive linker to a growth inhibitory or cytotoxic agent. The cytotoxic agent can be monomethylauristatin (MMAE), maytansinoid or calicheamicin, and the peptidase-sensitive linker can be a valine-citrulline (vc) linker. The antibodies are used for inhibiting unwanted cell growth.
Patent NZ-586979-A (NZ)
Title: Self-cleaning & de-polluting photocatalytic titanium dioxide based coating compositions
Inventor: STRATTON JOHN
IPC: B05D3/02
Filed: 2008-08-04
Abstract: A composition for forming a self-cleaning, de-polluting coating is disclosed, which comprises:(i) photocatalytic titanium dioxide; (ii) a binder component comprising a polysiloxane polymer and optionally one or more of an organic polymer selected from styrene polymer, styrene copolymer, acrylic polymer, acrylic copolymer, a styrene-acrylic copolymer and mixtures thereof; and (iii) an extender component comprising a mixture of calcium carbonate and an alternate extender, which is flash calcined kaolin clay;wherein the composition is capable of providing a coating on a substrate having superior durability as compared to an otherwise identical coating which does not comprise said alternate extender.
Patent NZ-587281-A (NZ)
Title: Mesoporous zinc oxide powder and method for production thereof
Inventor: MCCORMICK PAUL
IPC: A61K8/27
Filed: 2009-01-12
Abstract: Disclosed is a zinc oxide powder comprising zinc oxide aggregates which when used in a dispersion at a concentration of 10 wt% of zinc oxide, produces a transparent composition having a total visible transmittance through a path length of 20 microns at 550nm of at least one of; at least 70%, at least 75%, at least 80%, at least 85% or at least 93%, the powder having a number average zinc oxide aggregate size of at least 0.8 microns or at least 1 micron, wherein the aggregates are mesoporous and have a total mesopore volume of at least 0.25 cm3/g or at least 0.35 cm3/g or at least 0.5 cm3/g.
Patent NZ-591320-A (NZ)
Title: Shower water recycling system comprising at least one tank, pumps and valve
Inventor: CUMMINGS DOUGLAS PATRICK
IPC: A47K3/00
Filed: 2011-02-23
Abstract: A showering system (10) to limit the amount of water use is disclosed. The showering system (10) comprises a tank (40), pumps (30, 32), a water heater (50), a shower head (16), a shower base (18) and a valve (26). Firstly, the total amount of water to be used in a shower is stored in the tank (40) from which it is pumped to the shower head (16) by first pump (30). This water reaches the shower head (16) through the water heater (50). The water from the shower head (16) then falls to the shower base (18). This water at the shower base (18) passes to the valve (26) from where it is then either discharged to a sewer (27) or pumped backed to the tank (40) by second pump (32).
Patent NZ-593085-A (NZ)
Title: Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabine
Inventor: LEJEUNE PASCALE
IPC: A61K31/00
Filed: 2009-11-27
Abstract: Disclosed is a pharmaceutical combination comprising an antibody specifically recognizing CD38 and at least Cytarabine, wherein said antibody is capable of killing a CD38+ cell by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC).
Patent NZ-595310-A (NZ)
Title: Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis; vimentin fragments
Inventor: LING NICHOLAS CHI-KWAN
IPC: C07K1/107
Filed: 2010-03-26
Abstract: Patent No. 595310 Disclosed is a synthetic peptide comprising a first fragment of about 5 to about 50 contiguous amino acids of SEQ ID NO: 1 linked to at least a second fragment of about 5 to about 50 contiguous amino acids of SEQ ID NO: 1, wherein at least one residue of said first fragment is an arginine residue that is citrullinated, wherein at least one residue of said second fragment is an arginine residue that is citrullinated, and wherein the amino acids in said first fragment are not contiguous with the amino acids in said second fragment. SEQ ID NO: 1: MSTRSVSSSSYRRMFGGPGTASRPSSSRSYVTTSTRTYSLGSALRPSTSRSLYASSPGGVYATRSSAVRLRSSVPGVRLLQDSVDFSLADAINTEFKNTRTNEKVELQELNDRFANYIDKVRFLEQQNKILLAELEQLKGQGKSRLGDLYEEEMRELRRQVDQLTNDKARVEVERDNLAEDIMRLREKLQEEMLQREEAENTLQSFRQDVDNASLARLDLERKVESLQEEIAFLKKLHEEEIQELQAQIQEQHVQIDVDVSKPDLTAALRDVRQQYESVAAKNLQEAEEWYKSKFADLSEAANRNNDALRQAKQESTEYRRQVQSLTCEVDALKGTNESLERQMREMEENFAVEAANYQDTIGRLQDEIQNMKEEMARHLREYQDLLNVKMALDIEIATYRKLLEGEESRISLPLPNFSSLNLRETNLDSLPLVDTHSKRTLLIKTVETRDGQVINETSQHHDLE
Patent NZ-599153-A (NZ)
Title: Medical utility of glycan-binding proteins and glycans
Inventor: KUNZLER MARKUS
IPC: A61K38/16
Filed: 2010-10-12
Abstract: NZ 599153 Disclosed is a use of an N-glycan for the preparation of a medicament for use in the treatment and/or prevention of helminthic infections, wherein the N-glycan is selected from the group consisting of D-galacto-pyranosyl-β-1,4-L-fucopyranosyl-containing oligo/polysaccharides and/or glycoconjugates, D-galacto-pyranosyl-β-1,4-L-fucopyranosyl- α-1,6-GlcNAc-containing oligo/polysaccharides and/or glycoconjugates, and GnGnF6Gal- and/or MMF6Gal-containing oligosaccharides and glycoconjugates.
Patent NZ-601158-A (NZ)
Title: Data storage system and method for calibrating same
Inventor: MAHNAD FARAMARZ
IPC: G11B27/32
Filed: 2010-12-10
Abstract: A method of calibrating a data storage system and the data storage system are disclosed. The Data storage system comprises an optical media; an optical pick-up unit and at least one controller. The optical media has a gap dividing the media into segments having a plurality of tracks. Each exhibits fields of modulated wobble indicative of a physical track address. The optical pick-up unit is configured to detect the fields of modulated wobble and the at least one controller is operatively arranged with the pick-up unit and is configured to (i) record the physical track address of one of the tracks on one side of the gap. The pick-up unit has a position when detecting the fields of modulated wobble indicative of the physical track address of the one track. The at least one controller further is operatively arranged with the pick-up unit and is configured to (ii) maintain the position of the pick-up unit as the gap moves by the pick-up unit, (iii) record the physical track address of a first detected one of the tracks on the other side of the gap to calibrate the data storage system and (iv) assign a logical track address to the recorded physical track addresses.
Patent NZ-603476-A (NZ)
Title: Topical pharmaceutical composition comprising heparin
Inventor: VIRNO MICHELE
IPC: A61K47/14
Filed: 2011-05-02
Abstract: Disclosed is the topical pharmaceutical formulation comprising a solution of heparin and 5% to 15% of at least one polyoxyalkylene ester of a hydroxy fatty acid. Preferred polyoxyalkylene ester of a hydroxy fatty acid include a polyglycol ester of polyethylene glycol and 12-hydroxystearic acid (Macrogol 15 hydroxystearate).
Patent NZ-607667-A (NZ)
Title: Influenza viruses able to infect canids, uses thereof
Inventor: CRAWFORD PATTI C
IPC: C12N7/00
Filed: 2006-10-19
Abstract: Disclosed is a recombinant viral vector comprising a polynucleotide encoding a hemagglutinin (HA) comprising the amino acid sequence shown in SEQ ID NO:62, or a functional and/or immunogenic fragment thereof, or said polynucleotide encodes a polypeptide having 98% or greater sequence identity with the amino acid sequence shown in SEQ ID NO: 62, wherein the sequence is as defined in the complete specification. Also disclosed is a canine influenza vaccine, wherein the vaccine comprises a therapeutically effective amount of an influenza virus that is capable of infecting a canid animal, wherein said influenza virus comprises: i) a polynucleotide which encodes a polypeptide having the amino acid sequence shown in SEQ ID NO: 62, or a functional and/or immunogenic fragment thereof, or said polynucleotide encodes a polypeptide having 98% or greater sequence identity with the amino acid sequence shown in SEQ ID NO: 62; or ii) a polypeptide having the amino acid sequence shown in SEQ ID NO: 62, or a functional and/or immunogenic fragment thereof, or said polynucleotide encodes a polypeptide having 98% or greater sequence identity with the amino acid sequence shown in SEQ ID NO: 62.